
Autologous Bone Marrow Transplant—also known as an autologous stem cell transplant—is a sophisticated procedure used to treat various blood cancers and severe autoimmune diseases. This treatment involves using the patient's own healthy stem cells to "rescue" the bone marrow after it has been cleared of disease by high-dose chemotherapy or radiation. By utilizing the patient's own biological material, this procedure eliminates the risk of donor-related complications and provides a powerful pathway to remission.
Diagnosis of Multiple Myeloma where transplant is recommended as a primary frontline therapy.
Relapsed or refractory Hodgkin’s or Non-Hodgkin’s Lymphoma that has not responded to standard chemotherapy.
Certain germ cell tumors that have returned after initial treatment.
Severe, treatment-resistant autoimmune diseases such as Multiple Sclerosis (MS) or Systemic Sclerosis.
Presence of high-risk neuroblastoma in pediatric cases where aggressive therapy is required.
Recommendation for high-dose "conditioning" therapy that would otherwise permanently damage bone marrow function.
Multiple Myeloma requiring long-term marrow stabilization and disease control.
Relapsed Lymphoma where the goal is to achieve deep, durable remission.
Severe Crohn's Disease or other autoimmune conditions that have failed all standard biologic therapies.
Amyloidosis, a rare protein disorder that can affect organ function.
Specific types of leukemia that are in remission but carry a high risk of recurrence.
Stem cells are mobilized from the bone marrow into the bloodstream using growth factor injections.
Healthy stem cells are harvested via Apheresis, where blood is filtered through a specialized machine.
The collected stem cells are cryopreserved (frozen) and safely stored in a laboratory.
The patient undergoes high-dose "Conditioning" (chemotherapy or radiation) to eliminate remaining cancer cells.
The frozen stem cells are thawed and reinfused into the bloodstream, much like a standard blood transfusion.
The infused cells migrate to the bone marrow (Engraftment) and begin producing new, healthy blood cells.
Advanced Apheresis TechnologyHigh-efficiency cell separators that maximize the yield of healthy stem cells while reducing the time spent on the machine.
Next-Generation Mobilization AgentsThe use of precision medications that more effectively push stem cells into the bloodstream, even for "poor mobilizers."
Real-Time CD34+ TrackingSophisticated laboratory monitoring that identifies the exact hour of peak stem cell concentration for optimal harvesting.
Targeted Conditioning RegimensRefined chemotherapy protocols designed to maximize cancer cell death while minimizing damage to healthy organs.
Rapid Engraftment MonitoringMolecular tools that detect the earliest signs of new blood cell production, allowing for faster discharge from the hospital.
Automated Thawing SystemsDigitally controlled warming devices that protect the delicate cell membranes during the transition from ice to infusion.
Extensive physical evaluation to ensure the heart, lungs, and kidneys can tolerate high-dose therapy.
Dental clearance to eliminate any hidden sources of infection before the immune system is suppressed.
Placement of a central venous catheter (PICC or Hickman line) for easy blood access and infusion.
Coordination of a 3-to-6-week hospital stay in a specialized, HEPA-filtered isolation room.
Nutritional optimization and psychological counseling to prepare for the intensive recovery period.
Bone Marrow Aspiration and Biopsy to confirm the status of the underlying disease.
High-resolution PET/CT scans to map the location and extent of any remaining cancer cells.
Echocardiogram or MUGA scan to assess cardiac output and heart health.
Pulmonary Function Tests (PFTs) to ensure the lungs can handle systemic treatment.
Comprehensive blood panels, including viral markers and organ function profiles.
Eliminates the risk of Graft-versus-Host Disease (GVHD), as the body recognizes the cells as its own.
Allows for the use of "curative" doses of chemotherapy that would be impossible without a stem cell rescue.
Features high success rates, with durable remission seen in a significant majority of Multiple Myeloma patients.
Significantly improves survival outcomes and quality of life in relapsed lymphoma cases.
Offers a potential "reset" for the immune system in patients with aggressive autoimmune disorders.
The "Engraftment" phase typically takes 10 to 14 days, during which the patient is closely monitored for infections.
Daily blood counts are performed to track the rise of white blood cells, red blood cells, and platelets.
Supportive care, including blood transfusions and IV antibiotics, is provided until the new marrow is functional.
Patients remain in a protective environment until their absolute neutrophil count reaches a safe level.
Long-term follow-up involves monitoring for "late effects" and ensuring the disease remains in remission.
Gradual return to daily activities as the immune system slowly recovers over several months.
Long-term disease management, which may include maintenance therapy to prevent recurrence.
Re-vaccination protocols, as the transplant often "wipes out" previous immunity to childhood diseases.
Regular oncology or hematology check-ups with advanced imaging and blood markers.
Empowerment through the successful completion of one of the most intensive and effective medical treatments available